RAD June 2024 Abstracts and Posters
578 Cost per Responder in Brazil (EASI-75, EASI90 and ∆NRS ≥4) of biologics and JAK inhibitors Based on a Network-Meta-Analysis of Therapies for Atopic Dermatitis
Guilherme Muzy
594 United States Prevalence of Atopic Dermatitis in Adults by Race and Ethnicity
Andrew Alexis, Dave Nelson, Candrice Heath, Russel Burge, Beth Mitchell, Andrea Cohee, Evangeline Pierce, Amber Reck Atwater, Raj Chovatiya
603 Ruxolitinib cream 1.5% twice daily for the treatment of extensive atopic dermatitis in children aged 2–11 years: 52 week results from a maximum-use trial
Robert Bissonnette, MD, Mark S. Lee, MD, Seth B. Forman, MD, Linda Stein Gold, MD, PhD, Howard Kallender, PhD, Brett Angel, MD, Yutzu Kuo, PhD, Amy S. Paller, MD
618 A Bayesian network meta-analysis comparing the efficacy of dupilumab versus tralokinumab in adults with severe atopic dermatitis with inadequate response or intolerance to cyclosporin A
Patricia Guyot, Boya Chandrasekhar, Andrea Chiricozzi, Ronci Gianluca, Pedone Mariapaola, Kerry Noonan, Zhixiao Wang
619 Lebrikizumab improves signs and symptoms of moderate-to-severe atopic dermatitis in patients not adequately controlled or non-eligible for cyclosporine: a placebo-controlled, randomized phase 3 clinical study (ADvantage)
Richard B Warren, Marjolein de Bruin-Weller, Athanasios Tsianakas, Abdallah Khemis, Jacek C Szepietowski, H Chih-Ho Hong, Clara Armengol, Meritxell Falqués, Helena Agell, Eric Massana, Esther Garcia Gil, Stephan Weidinger
622 Shifting the care paradigm for individuals with skin of color (SOC): A comprehensive review of care gaps and emerging initiatives in dermatology
Andrew Alexis, Raj Chovatiya, Susan Taylor, Nada Elbuluk, Chesahna Kindred, Meena Hansen, Amber Reck Atwater, Maria Jose Rueda, Tanja Bosshard Becker, Vivian
623 Topical steroid withdrawal is a targetable overproduction of nicotinic acid from mitochondrial complex I overexpression
Nadia Shobnam, Grace Ratley, Sarini Saksena, Manoj Yadav, Prem Prashant Chaudhary, Ashleigh A Sun, Katherine N Howe, Manasi Gadkari, Luis M Franco, Sundar Ganesan, Katelyn J McCann, Amy P Hsu, Kishore Kanakabandi, Stacy Ricklefs, Justin Lack, Weiming Yu, Morgan Similuk and Magdalena A Walkiewicz, for the NIAID Centralized Sequencing Program, Donna D Gardner, Kelly Barta, Kathryn Tullos, Ian A Myles
624 Vitiligo biomarker CXCL10 correlates with clinical response in the phase 2 randomized, double-blind, vehicle-controlled TRuE-V mechanism of action study
Thierry Passeron, MD, PhD, Mark Lebwohl, MD, Charles Lynde, MD, Maryam Shayesteh Alam, MS, Vivian T. Laquer, MD, Jennifer Beecker, MD, Anand K. Ganesan, MD, Angelina Volkova, PhD, Babak Soltanalizadeh, PhD, Deanna Kornacki, PhD, Susan H. Smith, PhD
625 Efficacy and safety of 1.5% ruxolitinib cream in patients with facial and/or neck atopic dermatitis: a randomized, double-blind, decentralized phase 2 study
Zelma C. Chiesa Fuxench, MD, MSCE, Zhihong Lai, PhD, YuTzu Kuo, PhD, Haq Nawaz, MD, MPH, MBA, MS, Jonathan Cotliar, MD
626 Lebrikizumab is an effective treatment for moderate-to-severe atopic dermatitis in patients ≥60 years of age
April Armstrong, Matthew Zirwas, Maddalena Napolitano, Tiago Torres, Delphine Staumont-Salle, Amber Reck Atwater, Martin Dossenbach6, Helena Agell, Sherry Chen, Meihua Qiao, Evangeline Pierce, Maria Lucia Buziqui Piruzeli, Arash Mostaghi